Axsome Therapeutics AXSM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's net income?
- Axsome Therapeutics (AXSM) reported net income of -$64.54M in Q1 2026.
- How has Axsome Therapeutics's net income changed year-over-year?
- Axsome Therapeutics's net income decreased by 8.6% year-over-year, from -$59.41M to -$64.54M.
- What is the long-term trend for Axsome Therapeutics's net income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's net income has grown at a 8.9% compound annual growth rate (CAGR), from -$130.4M to -$183.17M.
- What does net income mean?
- The total profit or loss remaining after all expenses are paid.
- How do you interpret net income?
- Positive growth indicates increasing profitability, while a persistent loss may signal a need for capital raises or cost restructuring.
- How does net income compare across companies?
- Crucial for comparing bottom-line health across the biopharma industry, where high R&D spend often results in net losses.